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GUEST COMMENTARY
Diagnostic Mycobacteriology: Where Are We Today?
GARY V. DOERN*
University of Massachusetts Medical Center, Worcester, Massachusetts 01655
INTRODUCTION
Tuberculosis has reemerged as a significant public health
problem in certain parts of the United States. In addition,
strains of Mycobacterium tuberculosis with various patterns of
resistance to antituberculosis chemotherapeutic agents have
been recovered with increasing frequency (17, 18). The con-
tinuation of the human immunodeficiency virus (HIV) epi-
demic has contributed to both of these problems. In an attempt
to address the concurrent problems of the increasing preva-
lence of tuberculosis and more frequent recognition of multi-
drug-resistant strains of M. tuberculosis, the Centers for Dis-
ease Control and Prevention (CDC) in Atlanta, Ga., has
recently developed and now promulgates recommendations
for controlling the transmission of tuberculosis (2, 3).
Obviously, an essential component of any tuberculosis con-
trol program is rapid and accurate identification of infected indi-
viduals, especially those most likely to transmit viable organisms.
In this regard, the CDC has also developed recommendations for
standards of laboratory practice regarding detection, identifica-
tion, and susceptibility testing of M. tuberculosis in clinical
specimens (17). The three most fundamental aspects of these
recommendations are provision of acid-fast bacillus smear re-
sults within 24 h of specimen collection, isolation and identi-
fication ofM. tuberculosis within 10 to 14 days, and provision of
susceptibility test results within a total of 15 to 30 days. All
three of these objectives significantly impact on the function of
mycobacteriology sections of clinical microbiology laborato-
ries. Hours of operation, staffing patterns, technology deci-
sions, and the cost of providing service are all profoundly
influenced by these proposed standards of laboratory practice.
In particular, the second recommendation of the CDC, iso-
lation and identification ofM. tuberculosis within 10 to 14 days,
would have profound ramifications on the function of clinical
microbiology laboratories. A question arises: can this standard
be reasonably achieved using current “state-of-the-art” diag-
nostic methods? An important corollary to this question per-
tains to the recent licensure of a commercial molecular diag-
nostic test that will make it possible for even the smallest
laboratory to detect and identify M. tuberculosis directly in
clinical specimens in a matter of hours. What will be the role of
direct molecular diagnostic tests in mycobacteriology? What
are the performance characteristics of molecular detection as-
says? Use of such technologies would clearly permit laborato-
ries to meet the standard of 10 to 14 days for the isolation and
definitive species identification of M. tuberculosis. Will molec-
ular-probe based methods become broadly applied in clinical
microbiology laboratories? Should they be used routinely or
selectively? What are the fiscal implications of direct molecular
detection and identification? These issues serve as the basis for
this guest commentary.
Question: Are current CDC recommendations defining 10-
to 14-day limits on the recovery and definitive species identi-
fication of M. tuberculosis achievable by methods other than
direct nucleic acid amplification methods?
Answer: Probably not, at least in most laboratories.
Currently, the fastest and most reliable approach to detect-
ing and identifying M. tuberculosis in clinical specimens other
than use of a direct molecular detection test is use of a broth-
based radiometric or continuous monitoring detection system
with identification of clinical isolates recovered in culture using
a nucleic acid probe-based culture confirmation identification
system (8). Seen in Table 1 are the lengths of times to recovery
and identification of M. tuberculosis obtained in 10 U.S. labo-
ratories during 1993. All 10 laboratories employed a radiomet-
ric detection system and nucleic acid probes for identification
of isolates. Only 2 of these 10 laboratories, laboratories E and
G, met the CDC standard of 10 to 14 days for isolation and
identification of M. tuberculosis. The wide ranges observed for
mean lengths of time to detection and species identification
among the 10 laboratories described in Table 1 were explained
by differing staffing patterns, variable scheduling of mycobac-
teria specimen processing and workup of positive cultures, and
whether probe-based identification was applied directly to
growth in primary cultures or used only to characterize organ-
isms following at least one subculture. Both of the laboratories
that met the CDC’s recommended standard processed myco-
bacteriology specimens 7 days per week and aggressively at-
tempted probe-based identification whenever possible directly
on growth from primary cultures. In addition, laboratory E
worked up positive cultures with probe identification tests 7
days per week.
Question: Would application of nucleic acid amplification
assays for detection and identification of M. tuberculosis di-
rectly in clinical specimens permit laboratories to meet the
CDC’s recommended standard?
Answer: Possibly, at least for certain specimens.
One nucleic acid amplification assay for the detection and
identification ofM. tuberculosis directly in clinical material, the
MTD test (Gen-Probe, Inc., San Diego, Calif.), has recently
received Food and Drug Administration (FDA) approval and
is now available commercially. The MTD assay is a 4-h proce-
dure based on transcription-mediated amplification of a 16S
rRNA target sequence. Results are read with a luminometer.
A second amplification method, the Amplicor MTB procedure
(Roche Diagnostics Systems, Somerville, N.J.), is currently
awaiting FDA approval. The Amplicor MTB assay is predicted
on PCR amplification of a 584-bp segment of 16S rRNA; it
utilizes a thermocycler and requires 6 h to complete.
In addition to the MTD test and the Amplicor MTB assay,
three other direct nucleic acid amplification methods for de-
tecting M. tuberculosis are in various stages of development.
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These include an assay predicted on ligase chain reaction am-
plification of target nucleic acid segments (Abbott Diagnos-
tics), a second method based on PCR (Johnson and Johnson
Clinical Diagnostics), and finally, a technique which employs
strand displacement amplification technology (Becton-Dickin-
son Microbiology Systems).
Both the MTD test and the Amplicor MTB assay have been
extensively evaluated in clinical laboratories, and the results of
such evaluations have been described in the literature. The
overall sensitivity of the MTD test for detectingM. tuberculosis
appears to be 88 to 90%, with a specificity of ca. 98% (1, 10, 14,
15, 20). The Amplicor MTB assay appears to have slightly
lower levels of sensitivity (i.e., 75 to 80%) and a slightly higher
level of specificity (i.e., ca. 99%) (3, 20). Perhaps not surpris-
ingly, both assays demonstrate much higher levels of sensitivity
when applied to smear-positive specimens rather than to
smear-negative specimens: MTD test, 96 to 97% versus 75%;
Amplicor MTB assay, 95% versus 60%. This is undoubtedly
due to the fact that smear-positive specimens usually contain
larger numbers of organisms than do smear-negative speci-
mens.
With certain caveats, use of direct amplification assays for
M. tuberculosis would easily permit laboratories to meet the
CDC’s recommended standard for turnaround time for isolat-
ing and identifying M. tuberculosis, at least in specimens that
yield a positive probe result. Results are available the same day
the test is performed. The point can be made that direct nu-
cleic acid amplification assays will occasionally fail to detect
positive specimens in view of their lack of absolute sensitivity.
This, however, is not a valid reason to avoid use of these assays,
since the same statement can be made for culture. Indeed,
culture, which has generally been considered the definitive test
for detectingM. tuberculosis, is now recognized as having lower
levels of sensitivity than the MTD test and perhaps the Am-
plicor MTB assay. It is the very existence of direct molecular
assays that has permitted studies that demonstrate the lack of
absolute sensitivity of culture to be performed. At least part of
the enhanced sensitivity of amplification assays versus culture
for detecting M. tuberculosis may be explained by the ability of
such methods to detect nonviable organisms that would be
missed by culture. It should be noted, however, that positive
results obtained with the MTD test, the first direct test to
receive FDA approval, should be considered presumptive ac-
cording to the dictates of the FDA. An ancillary culture must
be performed in an attempt to recover an organism for defin-
itive identification.
Question: How should direct nucleic acid amplification as-
says be applied in the clinical microbiology laboratory?
Answer: This is a very complicated question with no obvious
single answer. However, in many settings the answer may be
“Not at all.”
The following discussion is predicated on the MTD test,
since it was the first to become commercially available. Fifty
tests are packaged in a single kit with this system. OneMTD kit
costs $1,500 (i.e., $30 per test) when purchased in volumes of
less than one kit per month. The cost is reduced to $1,387 per
kit when volumes of $1 kit per month are purchased (i.e.,
$27.74 per test). With the 1993 experience of the 10 laborato-
ries described in Table 1 as an indicator, a mean of 3,978
specimens were processed annually in individual laboratories
to yield a mean of 35 isolates of M. tuberculosis. On the basis
of the assumption that an individual laboratory would perform
the probe assay 5 days per week, i.e., 260 days per year, on
average 15 specimens would be processed during a given day.
This specimen volume would actually necessitate utilization of
19 tests, since ancillary tests (i.e., a positive and a negative
control and two internal standards) must be performed when
any number of clinical specimens are analyzed by the MTD
test. On the basis of this volume, the laboratory would qualify
for the volume discount, yielding pricing of $27.74 per test. The
actual cost per specimen would be slightly higher (i.e., $35.14),
however, because of the requisite controls and standards.
Over the course of an entire year, the laboratory would
spend more than $137,000 in supply costs alone for direct
detection of M. tuberculosis. Furthermore, among the 35 spec-
imens that would be expected to be positive during the year, 3
or 4 would be missed by the MTD test because of its 88 to 90%
sensitivity, resulting in 31 or 32 positive specimens by probe.
Typically, multiple positive specimens are received for individ-
ual patients. On the basis of a general estimate of 2 to 4
positive specimens per patient, the 31 or 32 positive probe
specimens would really represent only about 10 patients. In
other words, the cost associated with directly identifying an
individual patient as positive would be approximately $13,700,
and this figure pertains only to supply costs. If these costs were
amortized over the entire U.S. mycobacteriology testing expe-
rience, the financial burden on an already tenuous health care
economy would be staggering. Clearly, because of the way the
MTD test has been priced, in the context of its cost implica-
tions for individual laboratories as well as its fiscal impact
globally, it cannot be employed as a routine screen, irrespective
of how desirable its use might be. Simply put, it is unaffordable.
TABLE 1. Recovery of Mycobacterium spp. in 10 U.S. laboratories during 1993
Medical
center
No. of
specimens
Isolation of M. tuberculosis No. of isolates of:
No. of
isolates
Mean no. (range) of days to:
Detection Identificationa MAC Othermycobacteria
A 1,880 15 14 (6–24) 57 31
B 3,384 19 21 (8–39) 40 (9–76) 83 67
C 7,560 49 15 (3–43) 27 (7–72) 160 80
D 2,640 10 16 (7–36) 28 153 15
E 5,612 40 11 (3–22) 13 57 10
F 3,678 34 18 (4–37) 22 206 28
G 4,345 28 11 (4–25) 12 (5–25) 156 47
H 1,177 15 11 (3–27) 16 40 14
I 5,042 40 17 (4–26) 22 162 119
J 4,462 102 12 (1–50) 20 (4–57) 253 98
a In all cases, the length of time to identification listed in this table is predicated on when the specimen was received. In laboratories D, E, F, H, and I, the length
of time to identification was provided to the author as the period following detection. Therefore, no determination of ranges was possible.
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What about selective use of the MTD test? One approach
that is intuitively appealing is performance of the probe assay
only with smear-positive specimens. Indeed, the MTD test has
received FDA approval only for this application. Unfortu-
nately, because of the packaging employed in the MTD test,
this usage may also be cost-prohibitive, at least in many labo-
ratories. The 50 tests in the MTD kit are contained in a single
reagent vial that has a shelf life of 4 weeks once opened. Again
using estimates derived from the 1993 experience of the 10
laboratories outlined in Table 1, during the course of a year, an
average of 219 positive mycobacteria specimens (35 M. tuber-
culosis, 133M. avium complex (MAC), and 51 isolates of other
mycobacteria) would be derived from a mean of 3,978 speci-
mens processed. Using 60% as the aggregate detection sensi-
tivity of acid-fast bacillus smears for all three mycobacteria
groups (1, 5, 7, 10–13, 14–16, 20), roughly 131 of these 219
specimens would be expected to be smear positive. These 131
smear-positive specimens are likely to have come from approx-
imately 44 patients, again on the basis of the notion that 2 to 4
positive specimens per patient are generally submitted. If these
44 patients were distributed evenly over the course of 1 year,
on average ca. 3.4 unique patients with positive smears would
be seen during a given 4-week period. Since each reagent vial
from an MTD 50-test kit has a 4-week outdate, the entire vial
cost of $1,500 would be expended on those 3.4 patients: in
other words, the cost per smear-positive patient would be $441.
The annualized cost of applying the MTD test only to smear-
positive specimens from unique patients would be approxi-
mately $19,500. This $19,500 would presumably permit direct
same-day identification of an average of about 10 patients with
M. tuberculosis infections each year, i.e., $1,950 per patient.
Obviously, this per-patient cost estimate is based on a lab-
oratory experience in which a mean of 35 M. tuberculosis iso-
lates are recovered annually along with 133 isolates of MAC
and 51 isolates of other mycobacteria. These numbers repre-
sent averages derived from the collective experience of the 10
laboratories described in Table 1 in which the overall preva-
lence of M. tuberculosis among all positive specimens was ca.
16%. A second assumption is that the sensitivity of acid-fast
bacillus smears for M. tuberculosis, i.e., ca. 60% (1, 5, 7, 10–13,
14–16, 20), is also applicable to mycobacteria other than M.
tuberculosis. This may or may not be true. It is clear, however,
that by changing the relative prevalence of M. tuberculosis, the
cost-effectiveness of applying the MTD test to smear-positive
specimens also changes. Five of the laboratories in Table 1
(laboratories B, D, F, G, and I) had relative isolation rates of
M. tuberculosis of less than the mean of 16%, perhaps because
of disproportionately large HIV-positive patient populations
with attendant high relative rates of MAC recovery. Two lab-
oratories (laboratories A and C) were very close to the 16%
average M. tuberculosis recovery rate, while the remaining
three laboratories (laboratories E, H, and J) had high M. tu-
berculosis relative isolation rates. Clearly, the higher the rela-
tive prevalence of M. tuberculosis, the more cost-effective the
test becomes. To wit, the MTD test would be easiest to justify
in laboratories E, H, and J. Similarly, increasing the absolute
number of smear-positive patients with tuberculosis who are
investigated also would enhance cost-effectiveness.
The cost of the MTD test applied only to smear-positive
specimens could be dramatically decreased if the shelf life of
the reagent vial from the 50 test kit could be lengthened. This
vial contains a mixture of Mycobacterium enzymes and probe
reagent. One possibility would be to freeze small aliquots of
this mixture following reconstitution at2708C in an attempt to
lengthen the shelf life. Indeed, one anecdotal observation sug-
gests that the MTD amplification reagent is good for at least 6
months when frozen and stored at 2708C (19). It must be
cautioned, however, that FDA approval of the MTD test was
predicated on handling of the amplification reagent precisely
as described by the manufacturer, i.e., with no freezing.
The foregoing cost analyses has been restricted to costs
incurred by the laboratory. Although such costs are extremely
high, it is possible that they might be offset by other institu-
tional savings that would be realized through use of a nucleic
acid amplification assay for the direct detection of M. tubercu-
losis. In view of the high-level sensitivity of the MTD test when
applied exclusively to smear-positive specimens and its result-
ant high negative predictive value, when the MTD test is found
to be negative with a smear-positive specimen it is highly un-
likely that the patient from whom the specimen was derived
has tuberculosis. A negative result, therefore, could be con-
strued as indicating that precautions aimed at diminishing the
risk of transmission such as protective isolation would be un-
necessary. This could result in significant institutional cost sav-
ings.
Two institutional cost analyses pertaining to direct nucleic
acid amplification tests for M. tuberculosis have recently been
presented in abstract form (4, 6). Both were predicated on a
PCR-based assay for the direct detection of M. tuberculosis.
Interestingly, one study concluded that institutional cost sav-
ings clearly offset the cost of using PCR for direct detection of
smear-positive specimens (4), while the other study concluded
that the cost of direct PCR assay was not justifiable (6).
Clearly, more extensive studies are necessary before the overall
institutional cost-effectiveness of direct nucleic acid amplifica-
tion assays can be ascertained. Obviously, because of geo-
graphic and institutional differences in costs, such studies are
best conducted in one’s own institution. In the absence of such
data, it is difficult to justify the cost of at least the MTD test for
direct detection of M. tuberculosis.
CONCLUSIONS
The CDC has recently developed recommendations regard-
ing standards of practice in U.S. mycobacteriology laboratories
(15). One of these standards, the ability to isolate and defini-
tively identify M. tuberculosis from human clinical specimens
within 10 to 14 days, appears to be difficult to achieve in even
large academic medical center laboratories using any existing
technology other than direct molecular probe-based assays.
One such assay, the MTD test, has recently become commer-
cially available. Unfortunately, this test has been configured
and priced in such a way as to preclude its use in most labo-
ratories even for application only to smear-positive specimens
pending the availability of institutional cost savings data. Fur-
thermore, use of probe-based assays for direct detection of M.
tuberculosis in clinical specimens would have to be accompa-
nied by use of culture so as viable organisms would be available
for performance of antimicrobial susceptibility studies, another
CDC mandate.
These conclusions lead to two obvious assertions. First, the
CDC might consider revising its recommended standard for
length of time to isolation of M. tuberculosis. Second, the man-
ufacturer of the MTD test is urged to reconsider its pricing of
this product. There exist numerous factors that influence the
pricing of a diagnostic reagent. In the case of the MTD test,
clearly considerable development costs were incurred by the
manufacturer. Also, the process whereby the materials which
comprise this test are manufactured, packaged, and quality
controlled is likely to be very expensive. In addition, at an
enormous cost to the manufacturer, the MTD test languished
in the FDA for more than 4 years prior to approval. For these
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reasons, it may be that the current price per test of the MTD
test, $27 to $30, is necessary and justifiable. The reality is,
however, that this pricing will mitigate against extensive use of
this exciting new technology. If the MTD assay cost $5 per test,
this entire discussion would be moot. Arguably every labora-
tory performing mycobacteriology would adopt this test for all
specimens. One would think that nearly 100% of an entire
market at $5 per test would be considered more desirable than
virtually no market at a cost of $27 to $30 per test.
Finally, it should be emphasized that this discussion was
predicated on the MTD test because it is the first direct probe-
based assay to receive FDA approval and become commer-
cially available. The Amplicor MTB assay is currently pending
FDA approval. When it is licensed for distribution, depending
on its pricing, the foregoing analysis will be equally applicable.
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